{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:34:25Z","timestamp":1790724865089,"version":"4.1.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T00:00:00Z","timestamp":1357171200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1003106","type":"journal-article","created":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T00:49:32Z","timestamp":1357260572000},"page":"e1003106","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":173,"title":["Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs"],"prefix":"10.1371","volume":"9","author":[{"given":"Sam","family":"Hoot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen W.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland K.","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hangartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Diskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Noah","family":"Sather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis R.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Stamatatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1128\/JVI.01482-09","article-title":"Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables","volume":"84","author":"NA Doria-Rose","year":"2010","journal-title":"J Virol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e1001251","DOI":"10.1371\/journal.ppat.1001251","article-title":"Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1","volume":"7","author":"I Mikell","year":"2011","journal-title":"PLoS Pathog"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/JVI.02036-08","article-title":"Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection","volume":"83","author":"DN Sather","year":"2009","journal-title":"J Virol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"MD Simek","year":"2009","journal-title":"Journal of Virology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.7973652","article-title":"Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody","volume":"266","author":"DR Burton","year":"1994","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield","volume":"334","author":"R Pejchal","year":"2011","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"JF Scheid","year":"2011","journal-title":"Science"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"LM Walker","year":"2009","journal-title":"Science"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"X Wu","year":"2010","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1128\/JVI.01730-06","article-title":"Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa","volume":"80","author":"M Li","year":"2006","journal-title":"J Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.1213782","article-title":"Increasing the potency and breadth of an HIV antibody by using structure-based rational design","volume":"334","author":"R Diskin","year":"2011","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature10696","article-title":"Structure of HIV-1 gp120 V1\/V2 domain with broadly neutralizing antibody PG9","volume":"480","author":"JS McLellan","year":"2011","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"T Zhou","year":"2010","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1126\/science.1083182","article-title":"Antibody domain exchange is an immunological solution to carbohydrate cluster recognition","volume":"300","author":"DA Calarese","year":"2003","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature05580","article-title":"Structural definition of a conserved neutralization epitope on HIV-1 gp120","volume":"445","author":"T Zhou","year":"2007","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"9932","DOI":"10.1128\/JVI.00868-10","article-title":"Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop","volume":"84","author":"L Ching","year":"2010","journal-title":"J Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1128\/JVI.00411-11","article-title":"Binding Interactions between Soluble HIV Envelope Glycoproteins and Quaternary-Structure-Specific Monoclonal Antibodies PG9 and PG16","volume":"85","author":"TM Davenport","year":"2011","journal-title":"J Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1128\/JVI.77.10.5889-5901.2003","article-title":"Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design","volume":"77","author":"R Pantophlet","year":"2003","journal-title":"J Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1089\/08892220050058407","article-title":"Generation and structural analysis of soluble oligomeric envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV-1 isolates","volume":"16","author":"L Stamatatos","year":"2000","journal-title":"AIDS Res and Human Retroviruses"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 neutralization mediated by CD4-binding site antibodies","volume":"13","author":"Y Li","year":"2007","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/JVI.01992-08","article-title":"Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals","volume":"83","author":"Y Li","year":"2009","journal-title":"J Virol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/JVI.74.2.627-643.2000","article-title":"A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure","volume":"74","author":"JM Binley","year":"2000","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1128\/JVI.00389-08","article-title":"Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses","volume":"82","author":"Z Kraft","year":"2008","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/JVI.01691-07","article-title":"Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses","volume":"82","author":"Y Li","year":"2008","journal-title":"J Virol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1128\/JVI.75.12.5526-5540.2001","article-title":"The ability of an oligomeric human immunodeficiency virus type 1 (HIV- 1) Envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region","volume":"75","author":"SW Barnett","year":"2001","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1128\/JVI.00956-06","article-title":"Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian\/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection","volume":"80","author":"NR Derby","year":"2006","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"12148","DOI":"10.1128\/JVI.79.19.12148-12163.2005","article-title":"Comparing antigenicity and immunogenicity of engineered gp120","volume":"79","author":"S Selvarajah","year":"2005","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/aid.2007.0158","article-title":"Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140","volume":"24","author":"S Selvarajah","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1128\/JVI.76.11.5357-5368.2002","article-title":"Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization","volume":"76","author":"BK Chakrabarti","year":"2002","journal-title":"J Virol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1128\/JVI.02500-06","article-title":"Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity","volume":"81","author":"B Dey","year":"2007","journal-title":"J Virol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2006.10.032","article-title":"A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120","volume":"360","author":"S Beddows","year":"2007","journal-title":"Virology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JVI.73.2.1740-1745.1999","article-title":"Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5\/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals","volume":"73","author":"S Beddows","year":"1999","journal-title":"J Virol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1128\/JVI.79.14.8812-8827.2005","article-title":"Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1","volume":"79","author":"S Beddows","year":"2005","journal-title":"J Virol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"11214","DOI":"10.1128\/JVI.79.17.11214-11224.2005","article-title":"Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope","volume":"79","author":"NA Doria-Rose","year":"2005","journal-title":"J Virol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virol.2004.09.022","article-title":"Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins","volume":"331","author":"C Grundner","year":"2005","journal-title":"Virology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/157016207782418542","article-title":"Prospects of HIV Env modification as an approach to HIV vaccine design","volume":"5","author":"SL Hu","year":"2007","journal-title":"Curr HIV Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.1207532","article-title":"Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing","volume":"333","author":"X Wu","year":"2011","journal-title":"Science"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/v1030802","article-title":"Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies","volume":"1","author":"X Xiao","year":"2009","journal-title":"Viruses"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbrc.2009.09.029","article-title":"Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens","volume":"390","author":"X Xiao","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1128\/JVI.75.17.8340-8347.2001","article-title":"Antibody protects macaques against vaginal challenge with a pathogenic R5 simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro","volume":"75","author":"PW Parren","year":"2001","journal-title":"J Virol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.qco.0000200293.45532.68","article-title":"HIV-1 subtypes: epidemiology and significance for HIV management","volume":"19","author":"AM Geretti","year":"2006","journal-title":"Curr Opin Infect Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/QAD.0b013e328342ff93","article-title":"Global trends in molecular epidemiology of HIV-1 during 2000\u20132007","volume":"25","author":"J Hemelaar","year":"2011","journal-title":"AIDS"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1128\/JVI.68.8.4821-4828.1994","article-title":"Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1","volume":"68","author":"P Roben","year":"1994","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1128\/JVI.77.10.5863-5876.2003","article-title":"Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120","volume":"77","author":"MB Zwick","year":"2003","journal-title":"J Virol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1073\/pnas.89.19.9339","article-title":"Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro","volume":"89","author":"CF Barbas 3rd","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4049\/jimmunol.154.2.893","article-title":"Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure","volume":"154","author":"HJ Ditzel","year":"1995","journal-title":"J Immunol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1074-7613(00)80580-4","article-title":"Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate","volume":"8","author":"FD Batista","year":"1998","journal-title":"Immunity"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.1073\/pnas.97.19.10532","article-title":"A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago","volume":"97","author":"FR Cleghorn","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1084\/jem.20110363","article-title":"Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated","volume":"208","author":"HX Liao","year":"2011","journal-title":"J Exp Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"9998","DOI":"10.1128\/JVI.05045-11","article-title":"Analysis of a clonal lineage of HIV-1 envelope V2\/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors","volume":"85","author":"M Bonsignori","year":"2011","journal-title":"J Virol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"11725","DOI":"10.1128\/JVI.05680-11","article-title":"Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation","volume":"85","author":"SM Alam","year":"2011","journal-title":"J Virol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1128\/JVI.01687-09","article-title":"Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes","volume":"84","author":"CA Blish","year":"2010","journal-title":"J Virol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1128\/JVI.06363-11","article-title":"Engineering, Expression, Purification, and Characterization of Stable Clade A\/B Recombinant Soluble Heterotrimeric gp140 Proteins","volume":"86","author":"G Sellhorn","year":"2012","journal-title":"J Virol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2008-09-177139","article-title":"Engineering human hematopoietic stem\/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes","volume":"113","author":"XM Luo","year":"2009","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/JVI.65.9.5007-5012.1991","article-title":"Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity","volume":"65","author":"M Thali","year":"1991","journal-title":"J Virol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.65.11.6188-6193.1991","article-title":"Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody","volume":"65","author":"M Thali","year":"1991","journal-title":"J Virol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies","volume":"79","author":"M Li","year":"2005","journal-title":"J Virol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/088922202753747914","article-title":"HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus","volume":"18","author":"EM Long","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.vaccine.2009.10.028","article-title":"Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection","volume":"28","author":"G Sellhorn","year":"2009","journal-title":"Vaccine"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1128\/JVI.79.14.9069-9080.2005","article-title":"The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner","volume":"79","author":"CJ Saunders","year":"2005","journal-title":"J Virol"}],"updated-by":[{"DOI":"10.1371\/annotation\/ed7c0148-97eb-4416-824d-6e6d1aaeceef","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,7,5]],"date-time":"2013-07-05T00:00:00Z","timestamp":1372982400000}}],"container-title":["PLoS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1003106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T11:31:09Z","timestamp":1687951869000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1003106"}},"subtitle":[],"editor":[{"given":"Jeffrey","family":"Lifson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1003106","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,3]]}}}